Skip to main content
. Author manuscript; available in PMC: 2017 Jul 28.
Published in final edited form as: J Med Chem. 2016 Jul 13;59(14):6860–6877. doi: 10.1021/acs.jmedchem.6b00689

Chart 1.

Chart 1

Known nucleoside and nonnucleoside inhibitors of hAdK that have been examined in models of pain and/or seizures. Published potencies (IC50 values) for inhibition of the hAdK catalysis of the conversion of adenosine to AMP are given in nM.7,29

HHS Vulnerability Disclosure